These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 19738567)
1. [Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson's disease]. Levin OS; Nesterova OS; Otcheskaia OV; Zhuravleva EIu; Artemova IIu; Khozova AA; Ismailov AM; Lisenker LN; Vdovichenko TV; Rotor LD; Ganzula PA; Ivanov AK; Boĭko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):36-41. PubMed ID: 19738567 [TBL] [Abstract][Full Text] [Related]
2. [Effect of dopamine agonist pramipexole (mirapex) on tremor, affective disorders and quality of life in patients with Parkinson's disease]. Levin OS; Boĭko AN; Nesterova OS; Otcheskaia OV; Zhuravleva EIu; Artemova IIu; Khozova AA; Ismailov AM; Lisenker LN; Vdovichenko TV; Rotor LD; Ganzhula PA; Ivanov AK Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(2):39-44. PubMed ID: 20436448 [TBL] [Abstract][Full Text] [Related]
3. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. Lemke MR; Brecht HM; Koester J; Reichmann H J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808 [TBL] [Abstract][Full Text] [Related]
4. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823 [TBL] [Abstract][Full Text] [Related]
5. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211 [TBL] [Abstract][Full Text] [Related]
7. [Effects of the dopamine agonist mirapex (pramipexole) therapy on sleep disorders in Parkinson's disease]. Nodel' MR Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):42-7. PubMed ID: 20517225 [TBL] [Abstract][Full Text] [Related]
8. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease. Fedorova NV; Chigir' IP Neurosci Behav Physiol; 2007 Jul; 37(6):539-46. PubMed ID: 17657423 [TBL] [Abstract][Full Text] [Related]
9. New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease. Harada T; Ishizaki F; Horie N; Nitta Y; Yamada T; Sasaki T; Nagakane T; Yasumatsu Y; Nitta K; Katsuoka H Hiroshima J Med Sci; 2011 Dec; 60(4):79-82. PubMed ID: 22389951 [TBL] [Abstract][Full Text] [Related]
10. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease. Sung YH; Chung SJ; Kim SR; Lee MC Mov Disord; 2008 Jan; 23(1):137-40. PubMed ID: 17987649 [TBL] [Abstract][Full Text] [Related]
11. [Pramipexole in Parkinson disease. Results of a treatment observation]. Reichmann H; Brecht HM; Kraus PH; Lemke MR Nervenarzt; 2002 Aug; 73(8):745-50. PubMed ID: 12242961 [TBL] [Abstract][Full Text] [Related]
12. [Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease]. Fedorova NV; Chigir' IP Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):26-33. PubMed ID: 16841480 [TBL] [Abstract][Full Text] [Related]
13. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Künig G; Pogarell O; Möller JC; Delf M; Oertel WH Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884 [TBL] [Abstract][Full Text] [Related]
14. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Dooley M; Markham A Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397 [TBL] [Abstract][Full Text] [Related]